illumina

Morgan Stanley increased its price target on Illumina (NASDAQ: ILMN) from $78 to $84. At the same time, it increased its earnings per share estimates for the following three years and left its rating unchanged at Overweight. In a research report published today, Morgan Stanley states, "Our price...

Citigroup has raised the price target on Illumina (NASDAQ: ILMN) from $85 to $90 and maintains its Buy rating.

J.P. Morgan is out with its report today on Illumina (NASDAQ: ILMN), maintaining Overweight. In a note to clients, J.P. Morgan writes, "Illumina reported another exceptional quarter, with top- and bottom-line results again exceeding JPMe and consensus estimates. Despite the lack of an update on...

Piper Jaffray has raised the price target on Illumina (NASDAQ: ILMN) from $79 to $85 and maintains its Overweight rating.

Auriga, which upgraded shares of Illumina Inc. (NASDAQ: ILMN), is providing some color on the stock. “Post-earnings, Illumina shares drifted lower as worries about demand within Genome Wide Association Studies (GWAS), a convertible offering, and profit-taking all weighed,” Auriga writes. “...

Wedbush has issued a report reiterating the Outperform Rating of Illumina (NASDAQ: ILMN). Wedbush writes, "Shares likely to regain mojo over the remainder of 2011, in our opinion. Reaffirming OUTPERFORM. ILMN currently trades at a premium to the peer group on most metrics including PE (43x vs 18x...

Oppenheimer is assuming coverage of Life Technologies Corporation (NASDAQ: LIFE) and Illumina Inc. (NASDAQ: ILMN) due to a “reallocation of analyst resources.” “Our estimates, ratings, and price targets remain intact at this time,” Oppenheimer said. Life Technologies closed today at $49.32;...

Deutsche Bank reports that Illumina (NASDAQ: ILMN) will remain at a Buy Rating after its announcement to raise $800 million of convertible Senior Notes by 2016. The report stated, "We believe that today's announcement is a positive for the stock, given that some investors had viewed the increased...

Deutsche Bank has published a research report on Healthcare Services & Technology after President Obama released details on his FY2012 budget this morning. In the report, Deutsche Bank writes "The budget is primarily focused on deficit reduction, but the budget for the NIH was actually provided...

Late Friday (2/11), the House Appropriations Committee released details of its budget cuts proposal for the remainder of F2011 (ending 9/30) which will be voted on this week as HR 1, Citigroup reports. “According to the bill, the proposed NIH budget will be cut by $1.6B to $29.3B (-5%) vs. F2010...

Illumina, Inc. (NASDAQ: ILMN) reported 4Q2010 revenue/EPS of $261 mn/$0.29, in-line with the 1/11 preannouncement. “This represents yoy revenue growth of 47%,” Goldman Sachs writes. “HiSeq unit production increased another 30% sequentially, positioning the company to reduce lead times as promised...

Piper Jaffray has raised the price target on Illumina, Inc. (NASDAQ: ILMN) from $61 to $76 and maintains its Overweight rating.

JP Morgan has raised the price target on Illumina, Inc. (NASDAQ: ILMN) from $68 to $75 and maintains its Overweight rating.

Citigroup has raised the price target on Illumina (NASDAQ: ILMN) from $56 to $85 and maintains its Buy rating.

Morgan Stanley is raising its target on Illumina, Inc. (NASDAQ: ILMN) to $78 and continue to like the stock for 2011. “There are three keys to our positive thesis,” Morgan Stanley writes. “1) an emerging and underappreciated margin leverage story with Illumina on track to roughly double earnings...